Medline Inc (MDLN) Stock Forecast & Price Target

Medline has demonstrated strong financial performance, with sales revenue increasing by 11.47% year-over-year, rising from $25.51 billion to $28.43 billion for the 12 months ending December 2025. The company also reported an improvement in return on capital, which rose from 7.22% to 7.44%, and achieved significant growth through $2.4 billion in new customer signings driven by robust demand and volume strength. Forecasts suggest that Medline's revenue could rise by an additional 9.45% to reach approximately $31.12 billion, supported by the continued expansion of the Medline Brand, which now generates close to half of total revenue.

Medline's financial performance shows a significant downturn, with Economic Profit plummeting 220.79% year-over-year, resulting in a loss of $416.9 million compared to a gain of $345.1 million, primarily due to equity costs post-IPO. Additionally, Net Operating Profit After Tax (NOPAT) decreased by 12.66%, falling from $2.45 billion to $2.14 billion over the last twelve months, while Economic Operating Cash Flow (EBITDAR) also contracted by 4.48%, declining to $3.54 billion from $3.71 billion. The company's reliance on maintaining Prime Vendor agreements amid a challenging healthcare environment characterized by low margins, inflation, and increased competition poses further risks to revenue stability and market position.